These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 9580410)

  • 21. [Incidence of bacterial pneumonia in HIV-positive patients treated with preventive co-trimoxazole or pentamidine].
    Koch A; Kothe H; Braun J; Kämmerer R; Friedrich HJ; Dalhoff K
    Pneumologie; 1998 Nov; 52(11):614-21. PubMed ID: 9885511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does Pneumocystis carinii prophylaxis still need to be lifelong?
    Masur H; Kaplan J
    N Engl J Med; 1999 Apr; 340(17):1356-8. PubMed ID: 10219072
    [No Abstract]   [Full Text] [Related]  

  • 23. Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.
    Raboud JM; Montaner JS; Rae S; Kahn J; Hammer SM; Katzenstein DA; Pavia A; Dolin R; Hughes MD; Cross A; Beltangady M; Gatell J; Dunkle L; Smaldone L
    Antivir Ther; 1997 Dec; 2(4):237-47. PubMed ID: 11327443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pneumocystis carinii pneumonia in HIV-infected patients.
    May TA; Gruta CI; Goldschmidt RH
    Am Fam Physician; 2000 Oct; 62(8):1783, 1786. PubMed ID: 11057837
    [No Abstract]   [Full Text] [Related]  

  • 25. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV infection/acquired immunodeficiency syndrome at Siriraj Hospital, 2002: time for secondary prevention.
    Anekthananon T; Ratanasuwan W; Techasathit W; Rongrungruang Y; Suwanagool S
    J Med Assoc Thai; 2004 Feb; 87(2):173-9. PubMed ID: 15061301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis.
    Eigenmann C; Flepp M; Bernasconi E; Schiffer V; Telenti A; Bucher H; Wagels T; Egger M; Furrer H;
    Clin Infect Dis; 2003 Apr; 36(7):917-21. PubMed ID: 12652393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Primary and secondary prevention of Pneumocystis carinii pneumonia with pentamidine aerosol. Effectiveness, side effects and incidence of extrapulmonary Pneumocystis carinii manifestations].
    Stoehr A; Plettenberg A; Albrecht H; Stellbrink HJ; Meigel W; Begemann F
    Med Klin (Munich); 1994 Mar; 89(3):132-5. PubMed ID: 8196573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early versus deferred zidovudine monotherapy: impact on AIDS-free time and survival in the multicenter AIDS cohort study.
    Detels R; Muñoz A; Peng Y; Graham N; Mellors J; Phair J
    Antivir Ther; 1997 Jan; 2(1):21-9. PubMed ID: 11322263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P. carinii prophylaxis in patients with HIV.
    Kirchner JT
    Am Fam Physician; 1999 Nov; 60(7):2094-5. PubMed ID: 10569511
    [No Abstract]   [Full Text] [Related]  

  • 32. Patterns of morbidity and mortality in AIDS patients on Pneumocystis carinii prophylaxis who died during hospital admission: a report of 50 diseased patients.
    Hentzen BT; Schreij G
    Neth J Med; 1996 Sep; 49(3):101-5. PubMed ID: 8854672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Withdrawal of prophylaxis against Pneumocystis carinii pneumonia.
    Feinberg J
    Lancet; 1999 Apr; 353(9161):1287. PubMed ID: 10218521
    [No Abstract]   [Full Text] [Related]  

  • 34. Preaching what we practice: new guidelines for OI prophylaxis.
    Feinberg J
    AIDS Clin Care; 1999 Nov; 11(11):87-9, 94. PubMed ID: 11366709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on HIV/AIDS in Thailand.
    Ruxrungtham K; Phanuphak P
    J Med Assoc Thai; 2001 Jun; 84 Suppl 1():S1-17. PubMed ID: 11529320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.
    Hogg RS; Yip B; Kully C; Craib KJ; O'Shaughnessy MV; Schechter MT; Montaner JS
    CMAJ; 1999 Mar; 160(5):659-65. PubMed ID: 10102000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV infection and AIDS.
    Lloyd A
    P N G Med J; 1996 Sep; 39(3):174-80. PubMed ID: 9795558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.
    Justice AC; Stein DS; Fusco GP; Sherrill BH; Fusco JS; Danehower SC; Becker SL; Hansen NI; Graham NM;
    J Clin Epidemiol; 2004 Jan; 57(1):89-97. PubMed ID: 15019015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuing Pneumocystis carinii prophylaxis.
    Girard PM
    N Engl J Med; 2001 Jan; 344(3):222-3. PubMed ID: 11172146
    [No Abstract]   [Full Text] [Related]  

  • 40. A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy.
    Green H; Hay P; Dunn DT; McCormack S;
    HIV Med; 2004 Jul; 5(4):278-83. PubMed ID: 15236617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.